Featured Research

from universities, journals, and other organizations

New Drug-Coated Balloon Offers Hope for PAD

Date:
January 13, 2012
Source:
ProMedica
Summary:
Peripheral Artery Disease, also known as PAD, affects about eight million Americans. It is a narrowing of arteries in the arm or leg. The risk increases with age, and for people with high blood pressure, high cholesterol, or diabetes. The threat is even greater for smokers. People with PAD are four to five times more likely to suffer a heart attack or stroke. It can also lead to gangrene and amputation.

Peripheral Artery Disease, also known as PAD, affects about eight million Americans. It is a narrowing of arteries in the arm or leg. The risk increases with age, and for people with high blood pressure, high cholesterol, or diabetes. The threat is even greater for smokers. People with PAD are four to five times more likely to suffer a heart attack or stroke. It can also lead to gangrene and amputation.

Related Articles


Researchers at the Jobst Vascular Institute in Toledo, Ohio, are participating in one of the largest peripheral vascular studies ever and the first drug-coated balloon. Levant 2 is a global clinical trial studying the effectiveness of a new device called the Moxy Drug Coated Balloon compared to standard balloon angioplasty for the treatment of PAD. The Moxy balloon is coated with a drug called Paclitaxel which is currently used to treat a variety of diseases, such as certain types of cancer. It is also used as a coating on stents, which prop open blocked heart arteries. The device is inflated for 30 seconds in the narrowed vein and restores blood flow while coating the artery with the drug which may work to prevent re-blockage. Patients will be randomized to receive either treatment with the Moxy Drug Coated Balloon, or with a standard angioplasty balloon.

Jobst Vascular Surgeon John Pigott, MD, is performing a case study at ProMedica Toledo Hospital and says that he is encouraged by the preliminary results from first-in-man trials.

“This new device could significantly change the way PAD is treated in the future and may benefit a broad range of patients,” says Dr. Pigott.

Jobst Vascular Institute is a member of ProMedica, a mission-based organization that is ranked the No. 2 most integrated health system in the U.S. ProMedica was formed in 1986 and is a Toledo, Ohio-based, not-for-profit healthcare organization with nearly 14,000 employees; 3,000 physicians and more than 306 facilities in Ohio and Michigan. ProMedica serves more than 2.73 million patients annually and includes 11 hospitals; ProMedica Continuum Services with senior, hospice, rehabilitation, and integrative services; ProMedica Physicians, a network of more than 315 primary care and specialty physicians; and Paramount Health Care, the largest HMO in northwest Ohio.


Story Source:

The above story is based on materials provided by ProMedica. Note: Materials may be edited for content and length.


Cite This Page:

ProMedica. "New Drug-Coated Balloon Offers Hope for PAD." ScienceDaily. ScienceDaily, 13 January 2012. <www.sciencedaily.com/releases/2012/01/120113211009.htm>.
ProMedica. (2012, January 13). New Drug-Coated Balloon Offers Hope for PAD. ScienceDaily. Retrieved October 31, 2014 from www.sciencedaily.com/releases/2012/01/120113211009.htm
ProMedica. "New Drug-Coated Balloon Offers Hope for PAD." ScienceDaily. www.sciencedaily.com/releases/2012/01/120113211009.htm (accessed October 31, 2014).

Share This



More Health & Medicine News

Friday, October 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

U.S. Ebola Response Measures Demonstrated

U.S. Ebola Response Measures Demonstrated

AP (Oct. 31, 2014) Officials in the Washington area showed off Ebola response measures being taken at Dulles International Airport and the National Institutes of Health. (Oct. 31) Video provided by AP
Powered by NewsLook.com
Fauci Says Ebola Risk in US "essentially Zero"

Fauci Says Ebola Risk in US "essentially Zero"

AP (Oct. 30, 2014) NIAID Director Anthony Fauci said the risk of Ebola becoming an epidemic in the U.S. is essentially zero Thursday at the Washington Ideas Forum. He also said an Ebola vaccine will be tested in West Africa in the next few months. (Oct. 30) Video provided by AP
Powered by NewsLook.com
Nurse Defies Ebola Quarantine With Bike Ride

Nurse Defies Ebola Quarantine With Bike Ride

AP (Oct. 30, 2014) A nurse who vowed to defy Maine's voluntary quarantine for health care workers who treated Ebola patients followed through on her promise Thursday, leaving her home for an hour-long bike ride. (Oct. 30) Video provided by AP
Powered by NewsLook.com
Pot-Infused Edibles Raise Concerns in Colorado

Pot-Infused Edibles Raise Concerns in Colorado

AFP (Oct. 30, 2014) Colorado may have legalized marijuana for recreational use, but the debate around the decision still continues, with a recent - failed - attempt to ban cannabis-infused edibles. Duration: 01:53 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins